 |
|||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
|||||||||||||
|
Bexion’s Technology for Cancer
|
|||||||||||||||||||
|
A novel expressed human biologic targets tumors and causes cancer cell death through direct generation of ceramide, a known inducer of apoptosis.
Our First Target: Glioma Status:
§Tumor targeting demonstrated in xenograft, orthotopic, and metastatic tumors
§Preclinical efficacy in over 50 human cancer cell lines
§Efficacy in 7 tumor mouse models, and in hematological malignancies
§Strong safety profile
§Entering Phase 1 in 2009
|
|||||||||||||||||||
| Back | |||||||||||||||||||